Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSMO: Mepolizumab Switch Study in Severe Eosinophilic Asthma
NCT02654145Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 4 trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Started Mar 2016; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT02654145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654145.